- Home
- VTGN vs IRD Comparison
VTGN vs IRD Comparison
Compare VTGN & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- IRD
- Stock Information
- Founded
- VTGN 1998
- IRD 2018
- Country
- VTGN United States
- IRD United States
- Employees
- VTGN N/A
- IRD N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- IRD
- Sector
- VTGN Health Care
- IRD
- Exchange
- VTGN Nasdaq
- IRD NYSE
- Market Cap
- VTGN 59.8M
- IRD 59.1M
- IPO Year
- VTGN N/A
- IRD N/A
- Fundamental
- Price
- VTGN $3.08
- IRD $1.18
- Analyst Decision
- VTGN
- IRD Strong Buy
- Analyst Count
- VTGN 0
- IRD 3
- Target Price
- VTGN N/A
- IRD $6.33
- AVG Volume (30 Days)
- VTGN 374.7K
- IRD 282.6K
- Earning Date
- VTGN 08-12-2025
- IRD 08-15-2025
- Dividend Yield
- VTGN N/A
- IRD N/A
- EPS Growth
- VTGN N/A
- IRD N/A
- EPS
- VTGN N/A
- IRD N/A
- Revenue
- VTGN $486,000.00
- IRD $13,651,000.00
- Revenue This Year
- VTGN $23.83
- IRD $51.41
- Revenue Next Year
- VTGN $660.39
- IRD $68.84
- P/E Ratio
- VTGN N/A
- IRD N/A
- Revenue Growth
- VTGN N/A
- IRD N/A
- 52 Week Low
- VTGN $1.90
- IRD $0.65
- 52 Week High
- VTGN $3.79
- IRD $2.09
- Technical
- Relative Strength Index (RSI)
- VTGN 75.81
- IRD N/A
- Support Level
- VTGN $2.25
- IRD N/A
- Resistance Level
- VTGN $2.83
- IRD N/A
- Average True Range (ATR)
- VTGN 0.21
- IRD 0.00
- MACD
- VTGN 0.07
- IRD 0.00
- Stochastic Oscillator
- VTGN 84.16
- IRD 0.00
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.